A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

Launched by PRIOVANT THERAPEUTICS, INC. · May 22, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new medication called brepocitinib to see how safe and effective it is for adults with active, non-infectious uveitis, a condition that causes inflammation in the eyes. Specifically, the trial is looking at patients with intermediate, posterior, or pan uveitis, which means the inflammation affects different parts of the eye but is not caused by an infection. Researchers hope to determine if this treatment can help reduce symptoms and improve eye health.

To participate in the study, you must be an adult between 18 and 75 years old, diagnosed with non-infectious uveitis in at least one eye, and have a body weight over 40 kg. However, you cannot join if you have certain health conditions, like infectious uveitis, active cancer, or recent serious infections. If you qualify and decide to participate, you will receive the study medication and be closely monitored for any side effects or improvements in your condition. This trial is currently recruiting participants, and it offers a chance to help advance treatments for uveitis while receiving care from experienced medical professionals.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adult subjects (18-75 years old)
• • Diagnosis of non-infectious uveitis (intermediate uveitis, posterior uveitis, or panuveitis)
• • Active uveitic disease in at least 1 eye
• • Weight \> 40 kg with a body mass index ≤ 40 kg/m2
• Exclusion Criteria:
• Has confirmed or suspected current diagnosis of infectious uveitis History of or have:
• • 1. Lymphoproliferative disorder
• • 2. active malignancy
• • 3. cancer within 5 years prior to screening (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid carcinoma.)
• • 4. thrombosis orand cerebrovascularardiovascular ischemic event disease within the last 12 months
• • 5. a high risk for herpes zoster reactivation
• • 6. active or recent infections